CoreValve Results Set Path for Panel-Free Approval

A A
Medtronic expects smooth sailing for its CoreValve transcatheter aortic valve PMA, after the FDA took the rare step of saying clinical trial data on extreme-risk patients is so compelling that an advisory panel meeting won’t be needed.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00